Targeted SAP conjugates are powerful and specific lesioning agents used in the technique known as Molecular Surgery. The ribosome-inactivating protein, saporin (from the seeds of the plant, Saponaria officinalis) is bound to a targeting agent (anything that is recognized on the cell surface and internalized). The targeted conjugate is administered to cells (in vitro or in vivo). The targeting agent seeks out and binds to its target on the cell surface. The conjugate is internalized, saporin breaks away from the targeting agent, and inactivates the ribosomes which causes protein inhibition and, ultimately, cell death. Cells that do not have the cell surface marker are not affected.
RGR is a putative retinal G-protein coupled receptor. The protein acts as a photoisomerase to catalyze the conversion of all-trans-retinal to 11-cis-retinal. The reverse isomerization occurs with rhodopsin in retinal photoreceptor cells. RGR is expressed exclusively in tissue adjacent to retinal photoreceptor cells, the retinal pigment epithelium, and Muller cells. The RGR gene may be associated with autosomal recessive and autosomal dominant retinitis pigmentosa (arRP and adRP, respectively).
Anti-RGR-SAP eliminates cells expressing RGR. All other cells are left untouched.
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.